John J Englehardt

Title: Innovations of John J Englehardt

Introduction

John J Englehardt is a notable inventor based in El Cerrito, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapeutic antibodies. With a total of 2 patents, his work focuses on enhancing anti-tumor activity while minimizing side effects.

Latest Patents

Englehardt's latest patents include activatable anti-CTLA-4 antibodies and their uses. These antibodies are designed to have CTLA-4 binding activity specifically in the tumor microenvironment. The unique design includes a heavy chain with a VH domain and a light chain that comprises a masking moiety (MM) and a cleavable moiety (CM). The masking moiety is removed by tumor-specific proteases, allowing the antibodies to exhibit reduced binding to CTLA-4 outside the tumor. This innovative approach retains anti-tumor activity while significantly reducing the side effects associated with anti-CTLA-4 activity in non-tumor areas.

Career Highlights

Throughout his career, Englehardt has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Bristol-Myers Squibb Company and CytomX Therapeutics, Inc. His experience in these organizations has contributed to his expertise in developing cutting-edge therapeutic solutions.

Collaborations

Englehardt has collaborated with several professionals in his field, including Kimberly Ann Tipton and James William West. These collaborations have likely enriched his research and development efforts, leading to innovative advancements in antibody therapies.

Conclusion

John J Englehardt's contributions to the field of biotechnology, particularly through his patents on activatable anti-CTLA-4 antibodies, showcase his commitment to improving cancer treatment. His work exemplifies the intersection of innovation and therapeutic application, making a significant impact in the medical community.